PROSTATE-SPECIFIC ANTIGEN RESPONSE TO DEFERRED COMBINED ANDROGEN BLOCKADE THERAPY USING BICALUTAMIDE PREDICTS SURVIVAL AFTER SUBSEQUENT OESTROGEN AND DOCETAXEL THERAPIES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER

Authors

  • Marc B. Garnick


No abstract is available for this article.

Ancillary